At this time, there is no cure for polyglucosan body myopathy type 1. However, there are medications that can help manage the symptoms of the condition. These include medications to help with muscle weakness, such as corticosteroids, and medications to help with pain, such as non-steroidal anti-inflammatory drugs (NSAIDs). Physical therapy and occupational therapy can also help to improve muscle strength and function.

The primary risk factor for Polyglucosan body myopathy type 1 is a genetic mutation in the GBE1 gene. This gene mutation is inherited in an autosomal recessive pattern, meaning that both parents must pass on the mutated gene for a child to be affected. Other risk factors include a family history of the condition, being of Ashkenazi Jewish descent, and having a parent with the mutated gene.

The primary treatment for Polyglucosan body myopathy type 1 is supportive care. This includes physical therapy, occupational therapy, and speech therapy to help maintain muscle strength and function. Other treatments may include medications to help manage muscle spasms, pain, and fatigue. In some cases, surgery may be recommended to help improve mobility. Additionally, a healthy diet and regular exercise can help to maintain muscle strength and function.

Polyglucosan body myopathy type 1 (also known as Cori's disease) is caused by a mutation in the GBE1 gene, which is responsible for producing an enzyme called glycogen branching enzyme. This enzyme is responsible for breaking down glycogen, a type of sugar stored in the body, into smaller molecules. Without this enzyme, glycogen accumulates in the muscles, leading to the symptoms of Polyglucosan body myopathy type 1.

The most common symptoms of Polyglucosan body myopathy type 1 (also known as Cori's disease) include muscle weakness, muscle cramps, and muscle pain. Other symptoms may include difficulty walking, difficulty climbing stairs, and difficulty rising from a seated position. In some cases, people with this condition may also experience difficulty swallowing, breathing problems, and fatigue.

Polyglucosan body myopathy type 1 (also known as Lafora disease) is a rare, inherited neuromuscular disorder that affects the muscles and nervous system. It is caused by a mutation in the EPM2A gene, which leads to the buildup of polyglucosan bodies in the muscles and other tissues. Symptoms typically begin in childhood and include muscle weakness, seizures, and progressive loss of vision. There is currently no cure for Lafora disease, but treatments are available to help manage symptoms.